Two distinct peptides are listed: CJC-1295 (No DAC) / Modified GRF(1-29), and Ipamorelin / NNC 26-0161. An identity/research fact, not a Form Labs product claim.
Form Labs catalog record for CJC-1295 (No DAC) and IpamorelinNo-DAC and GHS-R1a research set
CJC-1295 (No DAC) & Ipamorelin
CJC-1295 (No DAC) and Ipamorelin are two distinct research peptides supplied together as laboratory reference materials.
Two peptides in one set, and they are studied together for a reason: both act on the system your body uses to release its own growth hormone, but they press two different buttons on the way in. Supplied freeze-dried, for laboratory research only.
Current lot pricing
$80.00 AUD
Base vial price: $80.00 AUD
Vial size10 mg
Ships from Perth, Australia PostFree standard shipping over $250Plain, discreet packagingStore at 2-8 C
Supplied strictly as reference material for in-vitro laboratory research. Not a medicine, supplement, or food. Not for human or veterinary use.
Research use onlyWhy this molecule is studied
Why researchers look at this pair.
Start with the chain. Deep in your brain, the hypothalamus sends a hormone called GHRH to the pituitary gland, telling it to release growth hormone. That is one way in, and CJC-1295 is a synthetic copy of that message - it presses the same button.
The second way in is stranger. Your stomach releases a hormone called ghrelin when it is empty, the one tied to feeling hungry. Ghrelin also, as it happens, prompts growth-hormone release - through a completely different receptor on that same gland. Ipamorelin acts on that one.
So the research question is easy to state: two separate signals arriving at the same gland by different routes. Does prompting the body's own release from two directions behave differently from prompting it from one? Neither peptide is growth hormone, and neither supplies any.
One thing to watch when reading around the subject. This is the short-acting version of CJC-1295; much of the older literature describes a modified long-acting form, and those results do not carry across. Ipamorelin's own clinical development was discontinued. Neither compound is an approved medicine.
This page is about that research and the batch you are getting. It is not for people or animals to take.
The research
What the published studies found.
Ipamorelin was first described by Raun and colleagues in 1998. An identity/research fact, not a Form Labs product claim.
Raun et al., European Journal of Endocrinology, 1998Ipamorelin is described as a five-amino-acid agonist at the ghrelin receptor. An identity/research fact, not a Form Labs product claim.
Howard et al., Science, 1996Figures outside lot paperwork describe third-party research records for the molecule. They are not Form Labs product results or use claims.
Read the full research guideIdentity, papers, and research-use boundariesMechanism notes
Plain-language research labels.
Two buttons on the same gland. Here is what each one is - the science in the papers, not a description of what these vials do.
CJC-1295 (No DAC)
A synthetic copy of GHRH - the message your brain normally sends to the pituitary gland telling it to release a pulse of growth hormone. This is the short-acting version, so the papers describe a brief signal rather than a sustained one. Its other research name is Modified GRF(1-29).
Ipamorelin
Presses a different button on the same gland - the receptor that normally listens for ghrelin, written GHS-R1a. Ghrelin is what your stomach releases when it is empty, the hormone tied to hunger, and it also prompts growth-hormone release. Ipamorelin is described as selective, meaning studies report it acting on that receptor without stirring up the other hormones ghrelin usually moves. First described in 1998 as NNC 26-0161; its clinical development was later discontinued.
Why the pair
Two separate signals reaching the same gland. Published work looks at whether prompting the body's own release pathway from two directions behaves differently from prompting it from one. Neither peptide is growth hormone or IGF-1, and neither supplies either directly.
Order anchor
Form Laboratories
CJC-1295 (No DAC) & Ipamorelin with live bundle pricing.
- Two peptide identities kept separate in the page copy, FAQ, and batch paperwork
- Lot CJCI-2506 shown beside the COA-backed identity and purity checks
- Freeze-dried research material with storage stated at 2-8 C
- Ships from Perth via Australia Post in plain packaging, with tracking emailed after dispatch
Base tier
$80.00 AUD
Single vial / 10 mg / $80.00 AUD per vial
Ships after order review. Reference material for research use only.
Testing documentation
Lot-level records
Australia-wide dispatch
Plain, tracked delivery
Plain fulfilment
Discreet outer packaging
Research use only
No human-use claims
COA proof
Batch paperwork before checkout.
98.4%
Measured purity is matched to the product record and batch paperwork.
Purity test (HPLC) result printed on the lab reportIdentity confirmed for CJC-1295 (No DAC) and IpamorelinLot CJCI-2506 tied to the batch paperwork
Certificate of AnalysisCJCI-2506
CompoundCJC-1295 (No DAC) & Ipamorelin
LotCJCI-2506
Purity98.4%
Net peptide10 mg
AppearanceFreeze-dried reference material
ReleasedCurrent product record
Download COA summary
Build your stack
Study alongside other catalogue references.
These products are shown as catalogue pairings only. Add any line to the same cart for order review.
Triple-receptor research peptide
Retatrutide
$149 AUD
Researchers can study this catalogue reference alongside CJC-1295 (No DAC) & Ipamorelin in the same order record.
Mitochondrial-derived peptide
MOTS-C
$99 AUD
Researchers can study this catalogue reference alongside CJC-1295 (No DAC) & Ipamorelin in the same order record.
Two-peptide research set
BPC-157 & TB-500
$119 AUD
Researchers can study this catalogue reference alongside CJC-1295 (No DAC) & Ipamorelin in the same order record.
FAQ
Questions, answered plainly.
CJC/IPAM is supplied as laboratory research material only. It is 21+ only, not for human consumption, and not for veterinary use.
Yes. The product page lists lot, identity, purity, appearance, release status, and storage notes for CJC/IPAM.
Follow the label and matching COA paperwork. This page repeats 2-8 C storage guidance and light-protection notes before checkout.
CJC-1295 (No DAC) is a synthetic analog of growth-hormone-releasing hormone (GHRH), also called Modified GRF(1-29). It is the short-acting No DAC form, not the with DAC albumin-binding form. It is supplied as a research-use-only reference material, not an approved medicine.
Ipamorelin is NNC 26-0161, a selective growth-hormone secretagogue and five-amino-acid agonist at the ghrelin receptor, GHS-R1a. It was first described in 1998 and studied for the ghrelin-receptor pathway. Its clinical development was discontinued, and it is not an approved medicine.
CJC-1295 (No DAC) and Ipamorelin are studied together because they sit on two different GH-axis research pathways: GHRH analog research and ghrelin-receptor agonist research. Published context discusses the body's own GH release and related IGF-1 signalling. Neither peptide supplies GH or IGF-1 directly.
Neither CJC-1295 (No DAC) nor Ipamorelin is an approved medicine in Australia. Neither is listed on the ARTG, and the TGA has not evaluated either for safety, quality, or effectiveness. Form Labs supplies both strictly as laboratory research materials.
CJC-1295 and Ipamorelin are on the World Anti-Doping Agency (WADA) Prohibited List. Growth-hormone-releasing hormone analogs and growth-hormone secretagogues are banned in and out of competition. Current status should be confirmed directly with WADA.
A Form Labs order is placed through checkout, then paid by bank transfer using the invoice reference emailed for the order. Once the transfer clears, Form Labs packs the order and emails tracking. PayID or Osko transfers can clear faster.
Research use only means CJC-1295 (No DAC) and Ipamorelin are supplied as laboratory reference materials for in-vitro research. They are not medicines, supplements, foods, or materials for human or animal use. The page describes compound identity and published research context, not instructions for use.
Yes. Growth-hormone-releasing hormone (GHRH) analogs and growth-hormone secretagogues - including CJC-1295 and Ipamorelin - are on the World Anti-Doping Agency (WADA) Prohibited List and are banned in and out of competition. Athletes subject to anti-doping rules should confirm current status directly with WADA. Form Labs supplies both for laboratory research only, not for human use.
"For research use only" means CJC-1295 (No DAC) and Ipamorelin are supplied strictly as laboratory reference materials - for in-vitro research, not for use in or on humans or animals. They are not medicines, supplements, or food. Everything on this page describes published research and the identity of this batch, not instructions for use.
Form your biology
CJC-1295 (No DAC) & Ipamorelin, with the batch details visible.
Before the material is logged, lot CJCI-2506 should match the COA and both peptide identities should be checked against the batch paperwork.
Added to cart